Fresenius SE & Co. KGaA (FRE) is a Medical care facilities company in the Healthcare sector, listed on Deutsche Borse Xetra. This page provides the complete earnings calendar, dividend schedule, and financial data for Fresenius SE & Co. KGaA in 2026. The next earnings report is expected on November 4, 2026.
Next earnings date
04 Nov 2026
In 76 days
EPS estimate
0.89
Revenue estimate
6.7B
Past earnings
Latest earnings analysis
Fresenius SE & Co. KGaA missed consensus estimates in its latest earnings report, with EPS of USD 0.948 falling 5.2% short of expectations while revenue of USD 6.7 billion exceeded estimates by 0.1%. In the previous report both EPS and revenue missed expectations.
Next ex-dividend
—
Not scheduled
Next payment
—
Not scheduled
Dividend amount
—
Not available
Past dividends
| Ex-dividend | Payment | Amount |
|---|---|---|
| 25 May 2026 | 27 May 2026 | 1.22 |
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Fresenius SE & Co. KGaA (FRE) is scheduled to report earnings on November 4, 2026.
Fresenius SE & Co. KGaA (FRE) last reported earnings on August 6, 2026.
Fresenius SE & Co. KGaA (FRE) is listed on Deutsche Borse Xetra.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.